Noven Pharmaceuticals won approval from the U.S. Food and Drug Administration for the company’s transdermal schizophrenia patch.
FDA approves Amneal’s generic dementia patch
Alzheimer’s Disease, Approvals, Biologics, Biosimilars, Department of Health and Human Services (HHS), Drug Competition Action Plan, FDA, FDA/Regulatory, Generics, J.P. Morgan Healthcare Conference, Market Value, Parkinson’s disease, Patches, Patent Litigation, Product Pipelines, Transdermal PatchesThe U.S. FDA approved Amneal Pharmaceuticals’ generic version of Novartis’ Exelon Patch (Rivastigmine Transdermal System) for dementia related to Alzheimer’s and Parkinson’s diseases.
Aequus Pharmaceuticals Inc. announced an expansion of its relationship with Corium International Inc. to include the company’s long-acting transdermal patch AQS1303 for the treatment of nausea and vomiting in pregnancy.